Cargando…

BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm

BACKGROUND: While some studies suggest that the BRAF V600E mutation correlates with a high-risk phenotype in papillary thyroid microcarcinoma (PTMC), more evidence is necessary before this mutation can be used to help guide decision making in the management of small thyroid nodules. This study inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silver, Jennifer A., Bogatchenko, Mariya, Pusztaszeri, Marc, Forest, Véronique-Isabelle, Hier, Michael P., Yang, Ji Wei, Tamilia, Michael, Payne, Richard J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572458/ https://www.ncbi.nlm.nih.gov/pubmed/34742355 http://dx.doi.org/10.1186/s40463-021-00543-9

Ejemplares similares

Prevalence and aggressiveness of papillary thyroid carcinoma in surgically-treated graves’ disease patients: a retrospective matched cohort study
por: You, Eunice, et al.
Publicado: (2019)

Effect of Having Concurrent Mutations on the Degree of Aggressiveness in Patients with Thyroid Cancer Positive for TERT Promoter Mutations
por: Alohali, Sama, et al.
Publicado: (2023)

Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
por: Turkdogan, Sena, et al.
Publicado: (2020)

Mutational status may supersede tumor size in predicting the presence of aggressive pathologic features in well differentiated thyroid cancer
por: Semsar-Kazerooni, Koorosh, et al.
Publicado: (2022)

Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV(600E)-Positive Papillary Thyroid Cancer
por: da Silva, Sabrina Daniela, et al.
Publicado: (2022)

Preoperative prediction of non-invasive follicular thyroid neoplasm with papillary-like nuclear features: a Canadian single-Centre experience
por: Larouche, Vincent, et al.
Publicado: (2020)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

Detection of BRAFV600E in Liquid Biopsy from Patients with Papillary Thyroid Cancer Is Associated with Tumor Aggressiveness and Response to Therapy
por: Jensen, Kirk, et al.
Publicado: (2020)

Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer
por: Turkdogan, Sena, et al.
Publicado: (2018)

Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma
por: Anand, Nidhi, et al.
Publicado: (2021)

The McGill Thyroid Nodule Score’s (MTNS+) role in the investigation of thyroid nodules with benign ultrasound guided fine needle aspiration biopsies: a retrospective review
por: Khalife, Sarah, et al.
Publicado: (2016)

Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart review
por: Hier, Jessica, et al.
Publicado: (2021)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

The Mcgill thyroid nodule score – does it help with indeterminate thyroid nodules?
por: Varshney, Rickul, et al.
Publicado: (2015)

Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAFV600E Mutation
por: Poyrazoğlu, Şükran, et al.
Publicado: (2017)

Iodine nutritional status is not a direct factor in the prevalence of the BRAFV600E mutation in papillary thyroid cancer
por: Lin, Yan-Yu, et al.
Publicado: (2023)

The T4/T3 quotient as a risk factor for differentiated thyroid cancer: a case control study
por: Sasson, Mark, et al.
Publicado: (2017)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer
por: Yoon, Seokho, et al.
Publicado: (2015)

Unfavorable efficacy to (131)I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb
por: Zhang, Na, et al.
Publicado: (2017)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

Molecular mutations as a possible factor for determining extent of thyroid surgery
por: Krasner, Joshua R., et al.
Publicado: (2019)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Does the likelihood of malignancy in thyroid nodules with RAS mutations increase in direct proportion with the allele frequency percentage?
por: Hudson, Thomas J., et al.
Publicado: (2023)

Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma
por: Guo, Liang, et al.
Publicado: (2019)

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
por: Huang, Shuhui, et al.
Publicado: (2022)

Predicting BRAFV600E mutations in papillary thyroid carcinoma using six machine learning algorithms based on ultrasound elastography
por: Agyekum, Enock Adjei, et al.
Publicado: (2023)

The Difference in Clinical Behavior of Gene Fusions Involving RET/PTC Fusions and THADA/IGF2BP3 Fusions in Thyroid Nodules
por: Tali, George, et al.
Publicado: (2023)

Frozen section analysis and sentinel lymph node biopsy in well differentiated thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2013)

Characteristics of PTEN Mutation in Thyroid Tumours: A Retrospective Chart Review
por: Bandargal, Saruchi, et al.
Publicado: (2023)

Coexisting Molecular Alterations Increase the Risk of Malignancy in Thyroid Nodules with Copy Number Alterations
por: Rajab, Mohannad, et al.
Publicado: (2022)

Thyroidectomy for Graves’ Disease Predicts Postoperative Neck Hematoma and Hypocalcemia: A North American cohort study
por: Mohtashami, Sadaf, et al.
Publicado: (2021)

The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells()
por: Puli, Oorvashi Roy, et al.
Publicado: (2018)

Prognostic Indicators of EIF1AX-Mutated Thyroid Tumor Malignancy and Cancer Aggressiveness
por: Bandargal, Saruchi, et al.
Publicado: (2022)

The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules
por: Jooya, Alborz, et al.
Publicado: (2016)

EIF1AX mutation in thyroid tumors: a retrospective analysis of cytology, histopathology and co-mutation profiles
por: Elsherbini, Noha, et al.
Publicado: (2022)

Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm
por: Lee, Jin Seok, et al.
Publicado: (2022)

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2015)

Impact of BRAFV600E Mutation on Event-Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian Population
por: Nechifor-Boilă, Adela, et al.
Publicado: (2023)

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vhl25m048a73oko210j1c8v1i0